UNSPSC 51241517: Cyclopentolate/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.

UNSPSC 51241517 Cyclopentolate/phenylephrine, a Commodity code, covers ophthalmic pharmaceutical products that state and local health systems procure through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. Vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, hold contractual relationships with at least two of the three wholesalers with chargeback systems in place, and carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability insurance. Pricing evaluation weights price competitiveness most heavily at 75 percent, with fixed pricing (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent) forming the remainder.

MMCAP represents a multi-state cooperative purchasing model spanning Minnesota and Oregon, with proposals due March 26, 2026. The RFP indicates no specific set-aside designations or disadvantaged-enterprise restrictions in available documentation. Contract awards will take effect July 1, 2026, with new vendors receiving two-year terms and optional MMCAP extensions; incumbent responders' amendments will align with existing expirations through June 30, 2028. Vendors should expect performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting, missed onboarding timelines, or improper class-of-trade denials. Products must be available in the marketplace by May 15, 2026, comply with FDA requirements, and possess expiration dates of at least one year from manufacture with a minimum six-month shelf life. Award structure is at MMCAP's discretion—sole, dual, or multi-awards based on therapeutic considerations, product availability, and member-specific needs.